Cancer Research Annual Meeting 2010  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 35, 997-1002, April 1, 1975]
© 1975 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allen, J. R.
Right arrow Articles by Carstens, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allen, J. R.
Right arrow Articles by Carstens, L. A.

Dehydroretronecine-induced Rhabdomyosarcomas in Rats1

James R. Allen, Ih-Chang Hsu and Laurine A. Carstens

Department of Pathology, University of Wisconsin Medical School, Regional Primate Research Center and Food Research Institute, University of Wisconsin, Madison, Wisconsin 53706

Two groups of rats were given s.c. injections of either monocrotaline or its major detectable metabolite, dehydroretronecine, biweekly for 1 year. Tissues obtained from partial hepatectomies performed at 4 months on a portion of these animals showed that both compounds caused a decided inhibition of mitotic division in regenerating liver. Rhabdomyosarcomas developed at the site of dehydroretronecine injection in 51.6% of the rats and in 3.3% of the monocrotaline-treated rats. Metastatic lesions were recorded in 8.3% of these animals. In addition to the above, 10% of the monocrotaline-treated rats developed other tumors that included myelogenous leukemias, hepatocellular carcinomas, and pulmonary adenomas. These data indicate that either monocrotaline or its metabolite dehydroretronecine are capable of causing neoplastic transformations in the tissues of experimental animals.

1 This investigation was supported in part by USPHS Grants HL-10941, CA-13288, and RR-00167 from the NIH, and American Cancer Society Institution Research Grant IN-35M-11 to the University of Wisconsin. Primate Center Publication 14-016.

Received 10/30/74. Accepted 1/10/75.




This article has been cited by other articles:


Home page
ScienceHome page
M. Deinzer, P. Thomson, D. Burgett, and D. Isaacson
Pyrrolizidine alkaloids: their occurrence in honey from tansy ragwort (Senecio jacobaea L.)
Science, February 4, 1977; 195(4277): 497 - 499.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1975 by the American Association for Cancer Research.